Boston Scientific reported second-quarter revenue of $5.44 billion, a 7.5% increase from the same period last year, surpassing the Zacks Consensus Estimate of $5.38 billion. Earnings per share came in at $0.86, compared to $0.75 a year ago and above the consensus estimate of $0.83. U.S. revenue reached $3.43 billion, while rest-of-world revenue was $2.02 billion, both exceeding analyst projections. Within its segments, cardiovascular worldwide net sales grew 8.3% to $3.62 billion, and MedSurg worldwide net sales rose 5.9% to $1.82 billion. The stock has returned 7.9% over the past month, outperforming the S&P 500's 1.9% gain.
Boston Scientific CorpBoston Scientific reported Q2 revenue and EPS that beat estimates, with strong segment growth.
Salesforce.com Inc